Experimental Medicine and Immunotherapy
Major aim of the Department Experimental Medicine and Immunotherapy (EMI) is the development of novel diagnostic approaches and innovative targeted therapeutic strategies based on the human immune system. One of our core competences is the use of antigen-reactive B lymphocytes to isolate disease-specific antibodies. They are further improved by protein engineering to end up with recombinant fusion proteins as diagnostic or therapeutic tools to fight different human diseases.
During the last 20 years knowledge on the human immune system has dramatically increased. Part of which has been used to translate into the display of recombinant antibody fragments on the surface of bacteriophages (phage display) as one of the most potent technologies in medical biotechnology. We are using this method in combination with rational protein design to generate novel disease-specific fusion proteins as tailor-made tools in research, diagnosis and therapy.